Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model
Journal
Nuclear Medicine and Biology
Journal Volume
35
Journal Issue
5
Pages
623-634
Date Issued
2008
Author(s)
Chow, T.-H.
Lin, Y.-Y.
Hwang, J.-J.
Wang, H.-E.
Tseng, Y.-L.
Wang, S.-J.
Whang-Peng, J.
Ting, G.
Abstract
Colorectal carcinoma is a highly prevalent and common cause of cancer in Taiwan. There is still no available cure for this malignant disease. To address this issue, we applied the multimodality of molecular imaging to explore the efficacy of diagnostic and therapeutic nanoradiopharmaceuticals in an animal model of human colorectal adenocarcinoma [colorectal cancer (CRC)] that stably expresses luciferase (luc) as a reporter. In this study, an in vivo therapeutic efficacy evaluation of dual-nanoliposome (100 nm in diameter) encaged vinorelbine (VNB) and 111In-oxine on HT-29/luc mouse xenografts was carried out. HT-29/luc tumor cells were transplanted subcutaneously into male SCID mice. Multimodality of molecular imaging approaches including bioluminescence imaging (BLI), gamma scintigraphy, whole-body autoradiography (WBAR) and in vivo tumor growth tracing, histopathology and biochemistry/hematology analyses were applied on xenografted SCID mice to study the treatments with 6% polyethylene glycol (PEG) of 111In-NanoX/VNB-liposomes. In vivo tumor growth tracing and BLI showed that tumor volume could be completely inhibited by the combination therapy with 111In-VNB-liposomes and by chemotherapy with NanoX/VNB-liposomes (i.e., without Indium-111) (P<.01). The nuclear medicine images of gamma scintigraphy and WBAR also revealed the conspicuous inhibition of tumor growth by the combination therapy with 111In-VNB-liposomes. Animal body weights, histopathology and biochemistry/hematology analyses were used to confirm the safety and feasibility of radiopharmaceuticals. A?synergistic therapeutic effect on CRC xenografted SCID mice was proven by combining an Auger electron-emitting radioisotope (Indium-111) with an anticancer drug (VNB). This study further demonstrates the beneficial potential applications of multimodality molecular imaging as part of the diagnostic and therapeutic approaches available for the evaluation of new drugs and other strategic approaches to disease treatment. ? 2008.
Subjects
111In-oxine; Bioluminescence imaging; Colorectal adenocarcinoma; Gamma scintigraphy; Luciferase; Vinorelbine; Whole-body autoradiography
SDGs
Other Subjects
8 quinolinol indium in 111; liposome; luciferase; navelbine; animal experiment; animal model; animal tissue; article; Auger electron spectroscopy; bioluminescence; cancer chemotherapy; cancer scintiscanning; colorectal carcinoma; computer system; controlled study; drug formulation; drug potentiation; drug safety; drug targeting; encapsulation; gamma scintigraphy; growth inhibition; histopathology; human; human cell; imaging system; isotope labeling; low drug dose; molecular imaging; mouse; nanotechnology; nonhuman; particle size; SCID mouse; scintillation camera; toxicity testing; tumor diagnosis; tumor growth; tumor model; tumor xenograft; whole body autoradiography; Animals; Antineoplastic Agents, Phytogenic; Autoradiography; Cell Proliferation; Drug Compounding; Genes, Reporter; HT29 Cells; Humans; Indium Radioisotopes; Liposomes; Luciferases; Luminescence; Male; Mice; Mice, SCID; Neoplasm Transplantation; Photons; Radiopharmaceuticals; Tissue Distribution; Vinblastine
Type
journal article